| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_949032f226a60fb42962963a9b59c16b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_98dc835c9532fb84eb3efce36ba02269
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ecccd87a5e4c773956f61ac2c1dca7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04f657a8261a2fc879c089c99e63eb0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_544d68c44073a6c0c837c4617888af35 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate |
2011-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e58fde457ae0867bd6dd0040fbce45da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ef75510f858166241ded4f0e7550d46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e8a2e98e24bedeed556944f8576f0e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc464b61690647b4dac5940796209e42 |
| publicationDate |
2016-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9371567-B2 |
| titleOfInvention |
Methods and kits to predict therapeutic outcome of BTK inhibitors |
| abstract |
Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed. |
| priorityDate |
2010-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |